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ABSTRACT  
Developing effective therapies for heart failure (HF) is challenging. Despite several clear 
successes in the development and delivery of pharmacotherapies for ambulatory patients 
with HF and reduced ejection fraction (HFrEF), efforts to modulate adverse neurohormonal 
activation beyond the renin-angiotensin-aldosterone system and the sympathetic nervous 
system generally have failed to improve outcomes further and have met with safety 
concerns including low blood pressure or changes in end-organ function. Recently, 
neprilysin inhibition in conjunction with angiotensin receptor blockade has been shown to 
improve outcomes. There is however no therapy approved specifically for HF with preserved 
EF (HFpEF) or for worsening chronic HF resulting in hospitalizations (WCHF; including 
acutely decompensated HF). Many patients with chronic HFrEF hav  poor outcomes despite 
receiving guideline-recommended therapies. Although preliminary results from some phase 
2 trials have been promising, many subsequent phase 3 trials have been neutral or negative, 
highlighting a disconnect in the translational process between basic science discovery, early 
drug development, and definitive clinical testing in pivotal trials. A major unmet need in the 
field of HF drug development is the ability to identify homogeneous subsets of patients 
whose underlying disease is driven by a specific mechanism that can be targeted using a new 
therapeutic agent. To understand better and address the array of challenges facing current 
HF drug development so that future eff rts have a better chance for success, the Food and 
Drug Administration facilitated a meeting on February 17th, 2015, which was attended by 
clinicians, researchers, regulators, and industry representatives. The following discussion 
represents the key messages from this meeting. 
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A PERSISTENT UNMET NEED FOR BETTER TREATMENTS FOR HEART FAILURE 
Morbidity and mortality in ambulatory patients with heart failure and reduced ejection 
fraction (HFrEF) has improved through neurohormonal modulation using renin-angiotensin-
aldosterone system (RAAS) blockade, beta-adrenergic blockade, and recently neprilysin 
inhibition.1, 2 However, substantial unmet needs persist, including worsening chronic HF 
(WCHF) and HF with preserved EF (HFpEF). Furthermore, ambulatory patients with HFrEF 
continue to have poor long-term outcomes.3 HF remains the most common cause of hospital 
admission for people aged >65 years in the United States.4 Over 80% of hospitalized HF 
patients have decompensated chronic HF, now termed WCHF,5 with l ss than 20% having a 
first-event (de-novo HF), or end-stage HF at admission.4, 5  
While rapid and substantial improvements in signs and symptoms are achieved 
during hospitalization, post-discharge outcomes for patients with WCHF remain poor, with 
≈25% readmission risk within 30-days 6, 7, and ≈30% mortality risk within 1 year of discharge.8 
Over the past two decades, despite advances in evidence-based therapies in ambulatory 
HFrEF; national policy measures to augment implementa ion of guideline recommendations; 
and the investment of billions of dollars and effort in trials of promising interventions for 
WCHF, there has not been a significant reduction in the post-discharge adverse event rate.8 
Also, no specific therapies have shown benefit in patients with either stable or WCHF with 
HFpEF. Potential reasons include the heterogeneity of the HFpEF syndrome (with poor 
matching of patients/pathophysiologies to appropriate therapies),9, 10 the lack of 
predictability of phase 2 studies, and uncertainties about the proper definition of HFpEF for 
enrollment into trials.11  
Thus the patients in most need for effective therapies remain without options. A 
disconnect thus exists between the promise of basic science, clinical research, and drug 
discovery and development; and the desired improvement in human health. Many causes 
have been cited for the recent negative trials in HF, including the drugs themselves, lack of 
phase 2 data, patient selection protocols, chosen clinical endpoints, and/or trial execution.12, 
13 Any one of these possibilities or their combination may underlie the reason that clinical 
findings observed in phase 2 trials have not been substantiated in phase 3 trials for HF.14 
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REACHING THE LIMIT OF BENEFIT FROM MODULATING THE NEROHORMORNAL 
ABNORMALITIES 
Neurohormonal agents such as RAAS blockers and beta-blockers undoubtedly have 
myocardial effects but their effects on the peripheral circulation are substantial. The 
majority of the current therapeutic armamentarium for HFrEF, including angiotensin 
converting enzyme-inhibitors, angiotensin receptor blockers, beta-blockers, hydralazine, 
nitrates, mineralocortoicoid receptor blockers, and neprilysin inhibitors all have blood 
pressure lowering effects that are often additive in an individual patient. While neprilysin 
inhibition with LCZ696 (valsartan/sacubitril) was recently shown to improve outcome in 
stable outpatients with HF symptoms beyond that achieved by the standard of care,1 all 
trials to date of treatments for patients with WCHF have been negative, which suggests that 
neurohormonally-focused strategies may have reached a point of diminishing return (Table 
1). In addition, further reducing blood pressure in HFrEF with therapies that cause 
vasodilation may increase the risk of myocardial injury and hypoperfusion of critical organ 
systems such as kidney, gut, and brain, with the potential for a J-shaped benefit curve. In 
HFpEF, modulation of the peripher l circulation is still an important possible therapeutic 
target; however, neurohormonal mo ulation with RAAS blockade or beta-blockade has 
failed to show major benefits in HFpEF. Thus, the heart remains a central target in HFpEF 
that has been understudied from a clinical trial standpoint. 
 
CARDIAC RESERVE IN HEART FAILURE VERSUS OTHER END-ORGAN FAILURE 
Unlike patients with kidney or liver failure where residual "tissue capital" is minimal at the 
point of organ failure and death, most patients with HF even at the point of death have 
abundance of cardiac reserve.15 Over two-thirds of the myocardial segments in patients with 
HFrEF have either no scar or scar limited to the subendocardium with <50% transmural 
involvement, revealing that these patient have amply viable myocardium and hence the 
potential to improve. Even patients with dilated hearts can show significant improvement 
with therapies such as beta-blockers.2 The majority of these treatment responders do not 
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have end-stage HF based on their blood pressure, renal function, biomarker profile, and 
rapid response to diuretics. Thus, in HFrEF, the potential for myocardial recovery is possible 
for many patients.  
These observations, when coupled with the recent failures of interventions targeting 
extra-cardiac manifestations of HF16, 17 generate the hypothesis that the heart should be the 
main therapeutic target for future HF drug developmental efforts. Thus, the potential to re-
engage residual capital in the heart to improve left ventricular function appears to represent 
a significant opportunity for eventual success in HF.  
 
THE HEART IS THE MAIN THERAPEUTIC TARGET 
Although it appears logical to focus on the heart as the main target of drug development for 
HF, this has not been the case historically. Industry representatives noted that internal HF 
research and development has now shifted to the heart itself, rather than following the 
approach of unloading the heart. Accordingly, the potential for development of 
pharmacotherapeutics targeting myocardial hibernation, energetics, cardiomyofiber isoform 
switching, and excessive apoptosis, among others, were cited as targets for which 
therapeutic strategies are being pursued by industry drug discovery and development. 
However, in order to fix the heart through appropriate intervention at one or more of these 
putative targets, we need to und rstand the specific defects that are present, and not 
merely identify that some uncharacterized defect must exist given that there is reduced 
function. Unfortunately, as a field we lag in understanding the development, evolution, and 
course of major cardiac abnormalities yielding pump dysfuction. These include abnormalities 
in the cardiomyocyte (e.g., signaling pathways, myofibrillar function, mitochondrial 
energetics, and calcium handling), in the interstitium, in the microcirculation, and in the 
varied interaction of these components (e.g. the effect of fibrosis on the microcirculation 
and vice versa). Abnormalities in the heart represent the proximal causes of HF, but much 
research to date has focused on the secondary effects of HF (e.g. neurohormonal activation, 
arrhythmias, congestion, hemodynamics, and renal function).  
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 The goal of direct cardiac modulation should be to slow and halt degradation of 
cardiac function, and then to reverse its clinical course back towards normal. It is important 
to realize that, barring beta-blockers and cardiac resynchronization, which alter secondary 
and primary HF abnormalities, other therapies such as RAAS modulation do not reverse 
cardiac function back to normal, though their population-level benefit in slowing or halting 
degradation of function cannot be minimized. Nevertheless, patients with persistently 
abnormal cardiac function need restoration therapies. Here, it is important to distinguish 
between transient and long-term restoration. Inotropes historically improve cardiac output 
acutely but cause myocyte damage and predispose to arrhythmias that precludes chronic 
use.18 New strategies should aim beyond a transient improvement in pump function and 
attempt to improve micro and macroscopic abnormalities, including those in interstitium, 
cardiomyocytes, cardiac microcirculation, and in metabolic pathways. In other words, they 
should aim to reverse the deleterious organ remodeling that has occurred at multiple levels.  
Currently, reverse remodeling in HFrEF is defined as improved EF or ventricular 
volumes; however, neither offers a direct assessment of myocardial function, and both are 
affected by preload and afterload.19 Furthermore, neither is applicable to HFpEF. To better 
create and evaluate effective, restorative HF therapies targeting the heart itself, reverse 
remodeling needs to be redefined as “a long-lasting improvement in myocardial function, 
with a concomitant recovery in structural (ventricular and atrial, fibrosis, vascular), electrical 
(conduction, arrhythmias), signaling pathways, and/or metabolic components.” An 
empirically testable early confirmation of efficacy would be evidence that improvements in 
function (systolic and/or diastolic) that lasts substantially longer than drug exposure. Thus, 
reverse remodeling encompasses both gross remodeling and remodeling on the cellular level. 
A simple, empirically testable consequence of this approach and early confirmation of its 
efficacy would be demonstrable improvements in function that last beyond drug exposure. 
These changes may include not only classic HF endpoints of mechanical function but also 
electrical and even metabolic function. Table 2 lists categories of cardiac-focused targets for 
HF therapies that greatly expand the traditional notions of reverse remodeling. Successful 
improvement in these markers will be most easily observed by their application to 
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etiologically homogeneous HF populations, for which an early assessment of response is 
key.  
 
THE NEED FOR DETAILED EARLY EVALUATION OF EFFECTS ON CARDIAC FUNCTION 
When considering the potential efficacy of a tested therapeutic, it is important not only to 
select homogeneous HF populations, but also to use technologies that provide metrics of 
early response to treatment. In this way one can obtain mechanistic insight if a positive 
signal is seen in a distinct pathway. An example would be the history of coronary disease 
drug development, in which assessment of drug impact on atherosclerotic plaque by 
intravascular ultrasound allowed early indications of disease-modifying effects of therapies. 
For HF, whether an intervention targets calcium signaling, microcirculation, mitochondria, or 
regeneration, analogous and relevant evaluation should include cardiac structure, function, 
perfusion, viability, fibrosis, and energetics. Although infrequently performed in HF trials,20 
the importance of understanding the cardiac substrate for better targeting of therapies 
cannot be overstated.9, 21 This is not to say that systemic pathways that contribute to disease 
progression, e.g. inflammation, should not be assessed. The focus, however, should be on 
whether such a systemic mechanism can modify pathways of disease and whether 
modulation of such mechanisms can improve the metrics of specific cardiac pathways. 
Proper use of animal mod ls and appropriate decision-making based on their results 
are important considerations, as animal testing and other preclinical studies will continue to 
play an important role in the development of new HF therapies. Given the modest record of 
HF drug developme t over the last two decades, no aspect of the discovery process should 
remain unexamined. Some improvements to past practices may be advisable. Often animal 
HF models are too simplistic, e.g. tachycardia-pacing model of systolic HF is unlikely to have 
the same level of microvascular or energetics dysfunction as a genetic metabolic disorder 
model leading to ventricular dysfunction. Hence, a generic model may not allow assessment 
of specific mechanistic aspects of the target pathway, and future models should be tailored 
to the question at hand. Although several animal models of HF exist,22 more are needed, and 
in particular there remains a pressing need for better animal models of HFpEF.  
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 9
With the caveat that there may be differences between the animal species and 
humans, it may be useful to conduct animal testing with standard-of-care therapies as 
background. This may require weeks of background treatment before initiation of the test 
drug to ensure that observed changes are driven by the intervention rather than initiation of 
background therapy. Thus will have cost and time consequences. Additionally, it is unclear 
which and how many background therapies should be included in animal studies.  
The importance of independent study replication, double-blind randomization, pre-
specification of analysis plans and outcome measures, independent core-lab analysis of 
imaging and other biomarkers, multicenter trials, among others are indisputable in clinical 
research, but these are rarely implemented in animal research. Though initial cost may be 
higher but may results in future cost savings of phase III trials which are negative because 
the tested therapeutic was incompletely validated in animal models. Other questions that 
include: (1) what are the best parameters in animal studies that might predict clinical benefit 
in humans?; (2) what is the magnitude of benefit in animals that is considered exciting and 
supportive of clinical experimentation?; and (3) what biomarkers included in clinical trial 
studies should be given more weight in animal studies? 
 A current handicap in HF drug discovery is our inability to measure improvements in 
human heart function prior to overt clinical events. Novel imaging options using advanced 
echocardiographic or cardiac magnetic resonance (CMR) imaging or other modalities may 
improve such evaluation,19 but will require dedicated protocols, and expertise and centers to 
perform them. In addition, molecular imaging with positron emission tomography (PET) can 
provide insights into pathophysiology, target receptor dynamics, quantitative assessment of 
the target of interest, drug dose and receptor engagement, and perfusion and metabolic 
state of the heart. For example PET can validate a molecular target of interest by showing 
abnormalities in HF patients compared to others and occupancy of the target by a novel 
pharmaceutical, thereby helping in early go/no-go decisions. This approach can used to save 
unnecessary trial enrollment and millions of dollars in drug development. An advantage of 
CMR and 3D over conventional 2D echocardiography is an improvement in reproducibility of 
measurements, leading to a reduction in the sample size needed to demonstrate a signal. 
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CMR has significant promise to improve our understanding of pathophysiology and 
to allow drug development to “return” to the heart as the organ of interest.23 Given its 
multi-faceted nature, CMR may be particularly useful in proof-of-mechanism studies for 
novel HF interventions, since this tool can assess multiple relevant anatomical and functional 
metrics upon which pathophysiological pathways converge. As noted earlier, whether an 
intervention targets calcium signaling, the microcirculation, mitochondrial biogenesis, 
substrate shifts, or myocardial regeneration, imaging biomarkers should include ventricular 
function, cardiac structure, and myocardial perfusion, viability and fibrosis, all of which can 
be measured by CMR.  
 
CLINICAL MODELS 
One of the benefits of research in animals is the homogeneity of the underlying cardiac 
substrate. However, the translation from findings in animals to humans is often problematic. 
One approach that weds the homogeneity of animal studies with the clinical applicability of 
human studies is the development of “clinical model”. Clinical models of HF are groups of 
prototypical patients who have a defined, uniform phenotype, and therefore may reflect a 
more homogeneous mechanistic b sis for the development of HF.  While it is acknowledged 
that some heterogeneity will remain, the goal is to minimize heterogeneity so future trials 
can be targeted towards specific types f patients. Patients can be grouped into clinical 
models using a variety of metrics, e.g. non-ischemic cardiomyopathy patients with no 
fibrosis is an example of a clinical model that could be targeted with specific therapies.    
Clinical models improve specificity and provide focus on the primary etiology and its 
pathophysiological consequences. This allows mapping of cellular and physiologic pathways 
and the potential for finding unique biomarkers that track when a target and pathway are 
engaged. The concept of testing a specific hypothesis in a small, well-defined cohort with a 
distinct pathophysiology has been termed the “T1 phase” of clinical development.24 During 
subsequent stages in larger cohorts, it will be important to demonstrate correlation 
between proof-of-mechanism target engagement biomarkers and proof-of-principle 
pathway engagement end-points, to understand if this pathway is altered only in the narrow 
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 11
initial cohort, or if it applies to larger more lengthy patient studies involving a more real-
world sampling of patients. Of course, the ultimate validation of this approach is to 
determine whether the altered pathway-specific surrogates predict adverse clinical events. 
An important limitation to the rational generation and testing of therapeutic 
hypotheses in the HF space is the difficulty in prospectively identifying patients whose 
disease is clearly driven by the mechanism of action to be tested. For example, it is not 
obvious how to segment patients into subsets where worsening HF is preferentially driven 
by a myocardial energy deficit, or poor relaxation due to stiffening by excess fibrosis, or 
poor relaxation due to a calcium-handling deficit. The inability to determine in a particular 
patient the primary mechanism underlying HF impairs our ability to test novel hypotheses. It 
is for these reasons that the development of defined clinical HF models is o important. The 
lack of clinical models is a hurdle that should not however inhibit future drug discovery. For 
the time being, if the selection of patients for proof-of-principle trial cannot yet be based on 
prospectively identifying patients in whom a single mechanism of action is responsible for 
driving the HF phenotype, it can still be based on if the target of the drug is embedded in the 
HF phenotype and, if so, whether the drug engages the target in that particular phenotype.  
 
PRACTICAL CONSIDERATIONS FROM INDUSTRY SPONSORS 
There is decreasing interest to fund large trials in HF when insurers are unwilling to pay for 
expensive drugs. The current reimbursement landscape, combined with the difficulty of 
selecting patients based on the identification of a specific mechanism of action responsible 
for the phenotype, represents a growing threat to the resourcing of new drug development. 
HF programs in the industry will continue to face internal pressure if they cannot credibly 
offer precision medicine strategies for management as investment opportunities are 
becoming more prevalent in other therapeutic arenas. HF drug discovery requires ample 
time and money to transition from preclinical to large, outcome-based studies. These 
features make HF drug development less appealing compared with other areas where it is 
easier to target a new medication to a distinct subset of patients who will likely benefit. For 
example, simple serum biomarkers or tissue biopsy results can be used to identify subsets of 
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cancer patients most likely to benefit from a candidate therapy. HF needs to develop 
analogous strategies in order to present better investment cases.  
An additional challenge facing HF drug development is the decreasing appetite to 
fund the large outcomes trials traditionally needed for registration. In contrast, other fields 
such as oncology make drug discovery more palatable by utilizing trial designs with softer 
outcomes measures such as progression-free survival that are still recognized as sufficient 
by regulatory bodies. Approaches to reduce sample sizes for morbidity and mortality trials 
by selecting high-risk patients must be balanced with the consideration that a positive 
response may be less likely in patients with end-stage disease.  
Accelerated approval allows a therapy to be approved in the United States on the 
basis of a surrogate end point thought “reasonably likely” to predict the ultimate clinical 
outcome of interest. Such approval comes with the obligation to verify that actual clinical 
benefit in the post-marketing setting. Perhaps some new therapy’s effects on a novel 
mechanism will sustain the case for being “reasonably likely”, but it will be necessary that 
the confirmatory study be considered feasible in order to use this regulatory pathway. For 
chronic therapy, this may be difficult. 
 
CONCLUSION 
Despite the growing problem, clinical trials have failed to produce positive results in WCHF 
and HFpEF. A variety of small and large animal models have been used to mimic the complex 
human HF phenotype, yet the transition from bench to bedside has borne little fruit, owing 
more to serendipity than to science. Future research, discovery, and development efforts in 
HF should have the heart as the principal target for therapy. Although laboratory science will 
continue to play an important role in the development of new therapies, its interpretation 
and use for decision-making must improve. Conduct of early phase translational research 
beginning with identification of well-phenotyped human patients for highly focused clinical 
trials investigating therapeutic mechanisms in human patients is critical for success. The 
advent of sophisticated cardiac imaging offers a novel approach to characterize and define 
the myocardium and interstitium creating phenotypic models of HF for enrollment. This 
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roadmap should help resolve some of the challenges of conducting clinical trials in HF, 
especially WCHF and HFpEF, with the ultimate goal of improving the outcomes of patients 
with HF worldwide. We believe that therapy targeting specific defects in cardiac structure 
and function in patients with WCHF and HFpEF have the best chance of improving the 
outcomes.  
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Table 1. Summary Points  
 
Point 1. Lack of therapies for WCHF and HFpEF continues to be a huge unmet need 
Mortality and morbidity in stable systolic dysfunction has improved by modulating neurohormonal abnormalities, but 
the long-term morbidity and mortality are still high, and we have failed in improving outcomes in WCHF and HFpEF.  
Point 2. Heart should be the focus of heart failure research and drug development 
Etiologies of cardiac origin represent the proximal causes of HF, but often interventions target issues secondary to the 
failing heart. Most patients die with considerable dysfunctional viable myocardium, unlike kidney, liver, or brain failure 
where residual "tissue capital" is minimal at the point of failure. 
Point 3. A potential path for a greater probability of translational success involves an early T1 mechanistic phase 
This is a two-step approach of demonstrating benefit in animal followed by testing of a hypothesis and agent in small 
“mechanistic clinical models" termed T1 trials investigating mechanism-function relationships using imaging and other 
biomarkers. Reverse remodeling should go beyond structural to include functional remodeling, including myocyte 
function effects on contractility, interstitial effects on contractility and relaxation, microcirculation, and metabolic and 
mitochondrial abnormalities. Irrespective of the models and analytical methods used, demonstration that target and 
pathway engagement by a hypothesized therapeutic intervention translat s into reversing cardiac/pump functional 
deficit in small, early T1 trials would build scientific, clini al, and regulatory confidence in the intervention under 
investigation, and thus promote advanced investigation in broader populations of heart failure patients. 
Point 4. Advanced imaging may be very useful in proof-of-mechanism studies for novel interventions 
Novel imaging can detect relevant anatomical an  functional features upon which many diverse pathophysiological 
pathways converge. Whether a drug targets calcium signaling, microcirculation, mitochondrial function, substrate 
shifts, or myocardial regeneration, clinically relevant biomarkers should include ventricular function, cardiac structure, 
perfusion, viability, and energetics, all of which can be inferred through advanced imaging.  
Point 5. Testing novel therapeutic hypotheses to extend healthy life in heart failure patients must continue  
Identifying homogeneous patients whose disease is clearly or more likely to be driven by the mechanisms of action 
involved in the therapeutic hypotheses to be tested with new agents is challenging but not limiting. Currently it is 
challenging to segment patients into subsets whose worsening state is driven by a particular mechanism. However, 
given the unmet need in WCHF and HFpEF, the testing of novel hypotheses for saving and extending healthy life in 
heart failure patients must continue aggressively. 
WCHF = worsening chronic heart failure; HFpEF = heart failure with preserved ejection 
fraction; RAAS = renin-angiotensin-aldosterone system; SNS = sympathetic nervous system  
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Table 2. Categories of Targets for Cardiac-Focused Heart Failure Therapies 
 
• Tissues 
o Cardiomyocytes 
o Extracellular matrix 
o Coupling of cardiomyocyte to extracellular matrix 
• Circulation 
o Coronary macrocirculation 
o Coronary microcirculation 
o Cardiac lymphatics 
• Whole organ coordination 
o Myocardial scar 
 Focal 
 Diffuse 
o Valvular heart disease 
o Synchrony 
 Electrical 
 Mechanical 
 Atrioventricular, interventricular, intraventricular 
o RV function 
• Metabolism 
o Glucose utilization 
o Mitochondrial function 
o Calcium handling  
• Vascular coupling 
o Venous/arterial interactions 
o Pulmonary/systemic interactions 
o Ventricular-vascular coupling 
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